Always speak with a licensed healthcare professional before starting, stopping, or changing any prescription medication or weight management plan
When compared to individuals taking DPP4 inhibitors, the GLP-1 group showed a recurrence risk of 14.4%, while the DPP4 inhibitor group had a risk of 23.3%
While many people will respond to Wegovy and Ozempic for weight loss, up to about 15% of people will not respond to the drugs
Condur, L
As GLP-1 medications, like Ozempic, continue to gain attention for their role in managing chronic conditions, HR and employee benefits professionals are increasingly fielding questions about coverageincluding for off-label uses like treating Polycystic Ovarian Syndrome (PCOS)
Both are reasonable, clinician-led options, and the better fit comes down to how you want to pay and how much hands-on contact you want